参考文献/References:
[1]Haanen JBAG,Carbonnel F,Robert C,et al. Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2017,28(suppl 4):iv119-iv142.
[2]郭潇潇，王汉萍，周佳鑫，等. 免疫检查点抑制剂相关心脏不良反应的临床诊治建议[J]. 中国肺癌杂志,2019,22(10):627-631.
[3]Ganatra S,Parikh R,Neilan TG. Cardiotoxicity of immune therapy[J]. Cardiol Clin,2019,37(4):385-397.
[4]Liu Y,Wang H,Deng J,et al. Toxicity of tumor immune checkpoint inhibitors-more attention should be paid[J]. Transl Lung Cancer Res,2019,8(6):1125-1133.
[5]Liu Y,Wu W. Cardiovascular?immune-related adverse events:evaluation,diagnosis?and?management[J]. Asia Pac J Clin Oncol,2020,16(4):232-240 .
[6]Mahmood SS,Fradley MG,Cohen JV,et al. Myocarditis?in?patients
treated?with?immune?checkpoint?inhibitors[J]. J Am Coll Cardiol,2018,71(16):1755-1764.
[7]Lyon AR,Yousaf N,Battisti NML,et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol,2018,19(9):e447-e458.
[8]Veronese G,Ammirati E. Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis:same disease,distinct challenges to face[J]. Int J Cardiol,2019,296:124-126.
[9]L?ubli H,BalmelliC,Bossard M ,et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma[J]. J Immunother Cancer,2015,3:11.
[10]Tarrio ML ,Grabie N ,Bu DX,et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis[J]. J Immunol,2012,188(10):4876-4884.
[11]Johnson DB,Balko JM,Compton ML,et al. Fulminantmyocarditis?with
combinationimmunecheckpointblockade[J]. N Engl J Med,2016,75(18):1749-1755.
[12]Grabie N,Lichtman AH,Padera R. T?cell?checkpoint?regulators?in the?heart[J]. Cardiovasc Res,2019,115(5):869-877.
[13]Zhang JC,Chen WD,Alvarez JB,et al. Cancer?immune?checkpoint blockade?therapy?and its?associated?autoimmune?cardiotoxicity[J]. Acta Pharmacol Sin,2018,39(11):1693-1698.
[14]Guo CW,Alexander M,Dib Y,et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies[J]. Eur J Cancer,2020,124:15-24.
[15]Moslehi JJ,Salem JE,Sosman JA,et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet,2018,391(10124):933.
[16]Escudier M,Cautela J,Malissen N,et al. Clinical?features,management,and?outcomes?of?immune?checkpoint?inhibitor-related?cardiotoxicity[J]. Circulation,2017,136(21):2085-2087.
[17]Hasson SP,Salwen B,Sivan A,et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis[J]. Clin Res Cardiol,2021,110(1):50-60.
[18]Asnani A. Cardiotoxicity of immunotherapy:incidence,diagnosis,and management[J]. Curr Oncol Rep,2018,20(6):44.
相似文献/References:
[1]孙文静,孙林,赵新湘.心脏核磁共振在急性心肌炎中的研究进展[J].心血管病学进展,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
SUN Wenjing,SUN Lin,ZHAO Xinxiang.Evolution of Cardiac Magnetic Resonance Imaging in Acute Myocarditis[J].Advances in Cardiovascular Diseases,2015,(7):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
[2]陈文浩 张焕基 郭攸胜 张东辉.活检证实病毒性心肌炎的治疗策略及预后[J].心血管病学进展,2019,(5):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
Chen WenhaoZhang HuanjiGuo YoushengZhang Donghui.Treatment Strategy and Prognosis of Viral Myocarditis Confirmed by Biopsy[J].Advances in Cardiovascular Diseases,2019,(7):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(7):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(7):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[5]王斯 魏欣 肖乾凤 陈晓平.心肌炎的分类及治疗进展[J].心血管病学进展,2021,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
WANG Si,WEI Xin,XIAO Qianfeng,et al.The Classification and Treatment Progress of Myocarditis[J].Advances in Cardiovascular Diseases,2021,(7):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
[6]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(7):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[7]孙睿 王阿曼.肿瘤免疫治疗相关动脉粥样硬化的研究进展[J].心血管病学进展,2023,(7):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
SUN Rui,WANG Aman.Atherosclerosis Associated with Cancer Immune Therapy[J].Advances in Cardiovascular Diseases,2023,(7):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
[8]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(7):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[9]陆睿 廖祎 王敏 林心情 鲁明军.免疫检查点抑制剂相关动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2024,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
LU Rui,LIAO Yi,WANG Min,et al.Research Progress on Mechanism and Clinical Significance of Immune Checkpoint Inhibitor Related Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(7):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
[10]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(7):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]